Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease
- PMID:22213086
- PMCID: PMC3499103
- DOI: 10.1002/hep.25559
Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease
Abstract
The Hedgehog (HH)-signaling pathway mediates several processes that are deregulated in patients with metabolic syndrome (e.g., fat mass regulation, vascular/endothelial remodeling, liver injury and repair, and carcinogenesis). The severity of nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome generally correlate. Therefore, we hypothesized that the level of HH-pathway activation would increase in parallel with the severity of liver damage in NAFLD. To assess potential correlations between known histologic and clinical predictors of advanced liver disease and HH-pathway activation, immunohistochemistry was performed on liver biopsies from a large, well-characterized cohort of NAFLD patients (n = 90) enrolled in the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Database 1 study. Increased HH activity (evidenced by accumulation of HH-ligand-producing cells and HH-responsive target cells) strongly correlated with portal inflammation, ballooning, and fibrosis stage (each P < 0.0001), supporting a relationship between HH-pathway activation and liver damage. Pathway activity also correlated significantly with markers of liver repair, including numbers of hepatic progenitors and myofibroblastic cells (both P < 0.03). In addition, various clinical parameters that have been linked to histologically advanced NAFLD, including increased patient age (P < 0.005), body mass index (P < 0.002), waist circumference (P < 0.0007), homeostatic model assessment of insulin resistance (P < 0.0001), and hypertension (P < 0.02), correlated with hepatic HH activity.
Conclusion: In NAFLD patients, the level of hepatic HH-pathway activity is highly correlated with the severity of liver damage and with metabolic syndrome parameters that are known to be predictive of advanced liver disease. Hence, deregulation of the HH-signaling network may contribute to the pathogenesis and sequelae of liver damage that develops with metabolic syndrome.
Copyright © 2012 American Association for the Study of Liver Diseases.
Figures












Comment in
- Paradoxical prosteatotic effect of hedgehog signaling pathway inhibition under conditions of steatosis.Gori M, Barbaro B, Arciello M, Balsano C.Gori M, et al.Hepatology. 2012 Oct;56(4):1587-8; author reply 1588. doi: 10.1002/hep.25729.Hepatology. 2012.PMID:22430986No abstract available.
- Hedgehog/hyaluronic acid interaction network in nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma.Pazzaglia S, Cifaldi L, Saran A, Nobili V, Fruci D, Alisi A.Pazzaglia S, et al.Hepatology. 2012 Oct;56(4):1589. doi: 10.1002/hep.25783.Hepatology. 2012.PMID:22505342No abstract available.
Similar articles
- Hedgehog pathway and pediatric nonalcoholic fatty liver disease.Swiderska-Syn M, Suzuki A, Guy CD, Schwimmer JB, Abdelmalek MF, Lavine JE, Diehl AM.Swiderska-Syn M, et al.Hepatology. 2013 May;57(5):1814-25. doi: 10.1002/hep.26230. Epub 2013 Apr 1.Hepatology. 2013.PMID:23300059Free PMC article.
- The intrahepatic signalling niche of hedgehog is defined by primary cilia positive cells during chronic liver injury.Grzelak CA, Martelotto LG, Sigglekow ND, Patkunanathan B, Ajami K, Calabro SR, Dwyer BJ, Tirnitz-Parker JE, Watkins DN, Warner FJ, Shackel NA, McCaughan GW.Grzelak CA, et al.J Hepatol. 2014 Jan;60(1):143-51. doi: 10.1016/j.jhep.2013.08.012. Epub 2013 Aug 23.J Hepatol. 2014.PMID:23978713
- Human germline hedgehog pathway mutations predispose to fatty liver.Guillen-Sacoto MJ, Martinez AF, Abe Y, Kruszka P, Weiss K, Everson JL, Bataller R, Kleiner DE, Ward JM, Sulik KK, Lipinski RJ, Solomon BD, Muenke M.Guillen-Sacoto MJ, et al.J Hepatol. 2017 Oct;67(4):809-817. doi: 10.1016/j.jhep.2017.06.008. Epub 2017 Jun 21.J Hepatol. 2017.PMID:28645738Free PMC article.
- The hedgehog pathway in nonalcoholic fatty liver disease.Verdelho Machado M, Diehl AM.Verdelho Machado M, et al.Crit Rev Biochem Mol Biol. 2018 Jun;53(3):264-278. doi: 10.1080/10409238.2018.1448752. Epub 2018 Mar 20.Crit Rev Biochem Mol Biol. 2018.PMID:29557675Free PMC article.Review.
- The adventures of sonic hedgehog in development and repair. II. Sonic hedgehog and liver development, inflammation, and cancer.Omenetti A, Diehl AM.Omenetti A, et al.Am J Physiol Gastrointest Liver Physiol. 2008 Mar;294(3):G595-8. doi: 10.1152/ajpgi.00543.2007. Epub 2008 Jan 24.Am J Physiol Gastrointest Liver Physiol. 2008.PMID:18218671Review.
Cited by
- Developmental origins of NAFLD: a womb with a clue.Wesolowski SR, Kasmi KC, Jonscher KR, Friedman JE.Wesolowski SR, et al.Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):81-96. doi: 10.1038/nrgastro.2016.160. Epub 2016 Oct 26.Nat Rev Gastroenterol Hepatol. 2017.PMID:27780972Free PMC article.Review.
- Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis.Hirsova P, Ibrahim SH, Bronk SF, Yagita H, Gores GJ.Hirsova P, et al.PLoS One. 2013 Jul 22;8(7):e70599. doi: 10.1371/journal.pone.0070599. Print 2013.PLoS One. 2013.PMID:23894677Free PMC article.
- Hepatocellular Ballooning is Due to Highly Pronounced Glycogenosis Potentially Associated with Steatosis and Metabolic Reprogramming.Ribback S, Peters K, Yasser M, Prey J, Wilhelmi P, Su Q, Dombrowski F, Bannasch P.Ribback S, et al.J Clin Transl Hepatol. 2024 Jan 28;12(1):52-61. doi: 10.14218/JCTH.2023.00242. Epub 2023 Oct 19.J Clin Transl Hepatol. 2024.PMID:38250461Free PMC article.
- Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer.Lade A, Noon LA, Friedman SL.Lade A, et al.Curr Opin Oncol. 2014 Jan;26(1):100-7. doi: 10.1097/CCO.0000000000000042.Curr Opin Oncol. 2014.PMID:24275855Free PMC article.Review.
- FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.Tillman EJ, Rolph T.Tillman EJ, et al.Front Endocrinol (Lausanne). 2020 Dec 14;11:601290. doi: 10.3389/fendo.2020.601290. eCollection 2020.Front Endocrinol (Lausanne). 2020.PMID:33381084Free PMC article.Review.
References
- Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112. - PubMed
- Larter CZ, Yeh MM, Haigh WG, Williams J, Brown S, Bell-Anderson KS, Lee SP, et al. Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. J Hepatol. 2008;48:638–647. - PubMed
- Choi SS, Omenetti A, Witek RP, Moylan CA, Syn WK, Jung Y, Yang L, et al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2009;297:G1093–1106. - PMC - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
- UL1RR02501401/RR/NCRR NIH HHS/United States
- U01DK061713/DK/NIDDK NIH HHS/United States
- U01DK061731/DK/NIDDK NIH HHS/United States
- U01DK061737/DK/NIDDK NIH HHS/United States
- U01DK061728/DK/NIDDK NIH HHS/United States
- U01 DK061730/DK/NIDDK NIH HHS/United States
- U01 DK061734/DK/NIDDK NIH HHS/United States
- M01RR020359/RR/NCRR NIH HHS/United States
- M01RR000827/RR/NCRR NIH HHS/United States
- U01DK061738/DK/NIDDK NIH HHS/United States
- UL1RR024128/RR/NCRR NIH HHS/United States
- U01 DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061713/DK/NIDDK NIH HHS/United States
- UL1 RR024989/RR/NCRR NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- UL1RR025741/RR/NCRR NIH HHS/United States
- U01 DK061731/DK/NIDDK NIH HHS/United States
- UL1RR02413101/RR/NCRR NIH HHS/United States
- U01 DK061718/DK/NIDDK NIH HHS/United States
- M01RR000065/RR/NCRR NIH HHS/United States
- P30 DK079637/DK/NIDDK NIH HHS/United States
- R01-DK077794/DK/NIDDK NIH HHS/United States
- M01 RR000188/RR/NCRR NIH HHS/United States
- UL1 RR025741/RR/NCRR NIH HHS/United States
- UL1 RR024131/RR/NCRR NIH HHS/United States
- U01DK061718/DK/NIDDK NIH HHS/United States
- U01DK061732/DK/NIDDK NIH HHS/United States
- M01 RR000750/RR/NCRR NIH HHS/United States
- K23-DK062116/DK/NIDDK NIH HHS/United States
- U01 DK061728/DK/NIDDK NIH HHS/United States
- R01 DK053792/DK/NIDDK NIH HHS/United States
- R01-DK053792/DK/NIDDK NIH HHS/United States
- M01 RR000065/RR/NCRR NIH HHS/United States
- K23 DK062116/DK/NIDDK NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- UL1 RR025014/RR/NCRR NIH HHS/United States
- UL1RR024989/RR/NCRR NIH HHS/United States
- U01 DK061738/DK/NIDDK NIH HHS/United States
- R01 DK077794/DK/NIDDK NIH HHS/United States
- M01 RR000827/RR/NCRR NIH HHS/United States
- M01RR00188/RR/NCRR NIH HHS/United States
- U01DK061734/DK/NIDDK NIH HHS/United States
- U01DK061730/DK/NIDDK NIH HHS/United States
- M01 RR020359/RR/NCRR NIH HHS/United States
- M01RR000750/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous